Published in J Autoimmune Dis on November 11, 2008
New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol (2009) 0.91
Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease. J Immunol Res (2014) 0.79
Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol (2015) 0.78
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med (1995) 8.08
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
The antiphospholipid syndrome. N Engl J Med (2002) 5.42
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA (2005) 3.27
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 2.81
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med (1992) 2.16
Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med (2000) 2.12
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am (2000) 1.82
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol (1997) 1.48
Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun (2000) 1.45
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Deep venous thrombosis. Hematology Am Soc Hematol Educ Program (2004) 1.41
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med (2005) 1.30
Estrogens, progestogens and thrombosis. J Thromb Haemost (2003) 1.22
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost (2006) 1.12
Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med (2002) 1.10
Thrombosis and the antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program (2005) 1.06
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum (2005) 1.05
Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum (2001) 1.02
Antiphospholipid antibodies and venous thromboembolism. Blood (1995) 1.02
Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis (2006) 1.00
Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost (2006) 0.97
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med (2007) 0.95
Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol (2006) 0.95
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus (1998) 0.95
Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Lupus (1997) 0.94
Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke (2005) 0.92
Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke (1992) 0.92
Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus (2005) 0.91
The treatment of venous thromboembolism in special populations. Thromb Res (2006) 0.87
Warfarin in antiphospholipid syndrome--time to explore new horizons. J Rheumatol (2005) 0.86
Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: what advice should we be giving? J Fam Plann Reprod Health Care (2001) 0.85
New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum (2003) 0.85
Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception (2004) 0.84
Management of the neurological manifestations of APS--what do the trials tell us? Thromb Res (2004) 0.84
Antiphospholipid syndrome: an evolving story. Blood Rev (2006) 0.84
Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology (2003) 0.83
Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome. Thromb Res (2004) 0.81
Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus (2003) 0.81
Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost (2005) 0.80
Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis (1996) 0.80
New anticoagulants. Semin Thromb Hemost (2003) 0.79
Thrombophilia: what's a practitioner to do? Hematology Am Soc Hematol Educ Program (2001) 0.78
Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost (2005) 0.78
Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke (1998) 0.77
How much warfarin is enough in APS related thrombosis? Thromb Res (2004) 0.76
A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. Contraception (1998) 0.76
Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation? J Autoimmun (2000) 0.76
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest (2009) 2.11
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol (2005) 1.58
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther (2009) 1.44
N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation. Isr Med Assoc J (2013) 1.43
Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol (2012) 1.05
Pulmonary renal vasculitis syndromes. Autoimmun Rev (2010) 1.02
A role for gut-associated lymphoid tissue in shaping the human B cell repertoire. J Exp Med (2013) 0.91
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs (2008) 0.87
Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med (2013) 0.87
Belimumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol (2014) 0.85
The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf (2008) 0.84
Antiphospholipid (Hughes) syndrome: beyond pregnancy morbidity and thrombosis. J Autoimmune Dis (2009) 0.83
Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) (2013) 0.83
Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica (2006) 0.81
Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag (2010) 0.80
B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun (2013) 0.79
Belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther (2012) 0.79
Mycophenolate mofetil in the treatment of lupus nephritis. Biologics (2008) 0.79
Anabolic steroid-induced rhabdomyolysis. Hosp Med (2005) 0.78
Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum (2005) 0.78
Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther (2014) 0.77
Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Ann Rheum Dis (2007) 0.77
Autoimmune rheumatic disease and sleep: a review. Curr Opin Pulm Med (2015) 0.76
Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol (2008) 0.76
Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. Immunotherapy (2015) 0.76
Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol (2014) 0.75
The treatment of lupus nephritis. BMJ (2005) 0.75
Correction. Immunoglobulin light chain allelic inclusion in systemic lupus erythematosus. Eur J Immunol (2015) 0.75
Orbital Inflammation as a Presenting Sign for CREST Syndrome. Ophthal Plast Reconstr Surg (2017) 0.75
Livedo Reticularis: An Enigma. Isr Med Assoc J (2015) 0.75
Clinical importance of autoantibodies in lupus nephritis. Expert Rev Clin Immunol (2007) 0.75
Practical management of lupus nephritis in pregnancy and the puerperium. Expert Rev Clin Pharmacol (2010) 0.75
The prevalence of abnormal pulse wave velocity, pulse contour analysis and ankle-brachial index in patients with livedo reticularis: a controlled study. Rheumatology (Oxford) (2013) 0.75
Acute manifestations of autoimmune connective tissue diseases. Br J Hosp Med (Lond) (2006) 0.75
Hepatic artery stenosis in antiphospholipid syndrome. Clin Appl Thromb Hemost (2011) 0.75